Trial Profile

A Phase 1/2 trial assessing EXS74539

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; EXS 74539 (Primary)
Indications Acute myeloid leukaemia; Small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms ENLYGHT

Most Recent Events

07 Jan 2025 According to Exscientia media release, the first patient is expected to be dosed in the Phase 1/2 ENLYGHT clinical trial in H1 2025.
07 Jan 2025 According to an Recursion Pharmaceuticals media release, in January 2025, the U.S. Food and Drug Administration (FDA) cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-4539.
15 Aug 2024 According to Exscientia media release, IND expected to be submitted later this year. The Company expects to initiate a Phase 1/2 clinical trial in early 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com